| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 20, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional investors for the purchase of an aggregate of 1,261,830 shares of its common stock and accompanying warrants to purchase up to an aggregate of 1,261,830 shares of its common stock, at a purchase price of $7.925 per share and accompanying warrant in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules. The warrants will have an
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advancement into Phase 3 development BOSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has received supportive feedback in an End of Phase 1 Type
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 study is evaluating a 7-peptide formulation of ELI-002 (ELI-002 7P) in patients with mutant KRAS ("mKRAS")-driven pancreatic ductal adenocarcinoma ("PDAC") who are at high risk of relapse following surgery. Elicio previously reported AMPLIFY-7P Phase 1a study results demonstrating a favorable safety profile, robust T-cell responses, antigen spread
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. "Megan and Thian are joining us at an exc
SCHEDULE 13G - Elicio Therapeutics, Inc. (0001601485) (Subject)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)